242 related articles for article (PubMed ID: 27669423)
1. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
Bergstrom CP; Ruffell B; Ho CM; Higano CS; Ellis WJ; Garzotto M; Beer TM; Graff JN
Anticancer Drugs; 2017 Jan; 28(1):120-126. PubMed ID: 27669423
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Garzotto M; Higano CS; O'Brien C; Rademacher BL; Janeba N; Fazli L; Lange PH; Lieberman S; Beer TM
Cancer; 2010 Apr; 116(7):1699-708. PubMed ID: 20143429
[TBL] [Abstract][Full Text] [Related]
3. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
Garzotto M; Myrthue A; Higano CS; Beer TM
Urol Oncol; 2006; 24(3):254-9. PubMed ID: 16678060
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Beer TM; Garzotto M; Lowe BA; Ellis WJ; Montalto MA; Lange PH; Higano CS
Clin Cancer Res; 2004 Feb; 10(4):1306-11. PubMed ID: 14977829
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
Galsky MD; Xie W; Nakabayashi M; Ross RW; Fennessy FM; Tempany CM; Choueiri TK; Khine K; Kantoff PW; Taplin ME; Oh WK
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):266-70. PubMed ID: 23712318
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
Oh WK; George DJ; Kaufman DS; Moss K; Smith MR; Richie JP; Kantoff PW
Semin Oncol; 2001 Aug; 28(4 Suppl 15):40-4. PubMed ID: 11685727
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
[TBL] [Abstract][Full Text] [Related]
14. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
17. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.
Schweizer MT; Huang P; Kattan MW; Kibel AS; de Wit R; Sternberg CN; Epstein JI; Eisenberger MA
Cancer; 2013 Oct; 119(20):3610-8. PubMed ID: 23943299
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
